Citalopram
Celexa, Citalopram (citalopram) is a small molecule pharmaceutical. Citalopram was first approved as Celexa on 1998-07-17. It is used to treat alcoholism, dementia, depressive disorder, diabetic neuropathies, and obsessive-compulsive disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter. In addition, it is known to target sodium-dependent noradrenaline transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Celexa, Citalopram (discontinued: Celexa, Citalopram)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Citalopram hydrobromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CELEXA | AbbVie | N-020822 RX | 1998-07-17 | 3 products, RLD, RS |
| CITALOPRAM HYDROBROMIDE | Almatica Pharma | N-215428 RX | 2022-01-31 | 1 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| celexa | New Drug Application | 2023-10-09 |
| citalopram | ANDA | 2025-09-11 |
| citalopram citalopram hydrobromide | ANDA | 2023-04-19 |
| citalopram hydrobromide | ANDA | 2025-06-09 |
| direct rx | ANDA | 2015-11-06 |
| perrigo citalopram | ANDA | 2010-02-25 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
709 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 21 | 59 | 68 | 124 | 100 | 355 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 22 | 56 | 67 | 109 | 86 | 323 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 16 | 48 | 54 | 82 | 60 | 252 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 6 | 6 | 13 | 16 | 15 | 52 |
| Healthy volunteers/patients | — | — | — | 24 | — | — | 4 | 7 | 35 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 5 | 6 | 8 | 19 |
| Treatment-resistant depressive disorder | D061218 | — | — | 2 | 1 | 7 | 3 | 5 | 18 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | 2 | 9 | 5 | 17 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 2 | 4 | 4 | 5 | 15 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 1 | 3 | 3 | 7 | 2 | 15 |
Show 100 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 1 | 5 | 1 | — | — | 6 |
| Hot flashes | D019584 | — | — | — | — | 1 | — | 4 | 5 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 2 | — | 1 | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | 1 | 4 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 2 | 2 | — | 1 | 3 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | 2 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | 1 | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 2 | — | — | 2 |
| Chronic pain | D059350 | — | — | — | 1 | 1 | — | 1 | 2 |
| Separation anxiety | D001010 | EFO_1001916 | — | 1 | — | 1 | — | — | 2 |
Show 35 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | 7 | 8 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | 2 | — | — | 1 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | 2 | 3 |
| Ischemic stroke | D000083242 | — | — | 1 | 3 | — | — | — | 3 |
| Autism spectrum disorder | D000067877 | — | F84.0 | 1 | 1 | — | — | 1 | 3 |
| Anhedonia | D059445 | — | R45.84 | 1 | 1 | — | — | 2 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 1 | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | 1 | 2 |
| Menopause | D008593 | EFO_0003922 | N95 | — | 1 | — | — | 1 | 2 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | 1 | 2 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | — | 2 | — | — | — | 1 | 3 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | 1 | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | 1 | 2 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
| Respiratory insufficiency | D012131 | — | J96.9 | 2 | — | — | — | — | 2 |
| Psychological stress | D013315 | — | — | 1 | — | — | — | — | 1 |
| Psychological well-being | D000092862 | — | — | 1 | — | — | — | — | 1 |
| Urinary incontinence | D014549 | — | R32 | 1 | — | — | — | — | 1 |
| Stress urinary incontinence | D014550 | — | — | 1 | — | — | — | — | 1 |
| Fecal incontinence | D005242 | — | R15 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 5 | 5 |
| Taste disorders | D013651 | — | — | — | — | — | — | 3 | 3 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 3 | 3 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 2 | 2 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 2 | 2 |
| Adolescent development | D041923 | — | — | — | — | — | — | 2 | 2 |
| Affective symptoms | D000342 | — | — | — | — | — | — | 2 | 2 |
| Perimenopause | D047648 | — | — | — | — | — | — | 1 | 1 |
| Intractable pain | D010148 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Show 48 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Citalopram |
| INN | citalopram |
| Description | 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile is a nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group. It is a member of 2-benzofurans, a nitrile, an organofluorine compound, a cyclic ether and a tertiary amino compound. It is a conjugate base of a 3-[5-cyano-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-1-yl]-N,N-dimethylpropan-1-aminium. |
| Classification | Small molecule |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21 |
Identifiers
| PDB | — |
| CAS-ID | 59729-33-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL549 |
| ChEBI ID | 77397 |
| PubChem CID | 2771 |
| DrugBank | DB00215 |
| UNII ID | 0DHU5B8D6V (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A4
SLC6A4
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Alternate
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Citalopram
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 22,933 documents
View more details
Safety
Black-box Warning
Black-box warning for: Celexa, Citalopram, Citalopram citalopram hydrobromide, Citalopram hydrobromide, Direct rx
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
88,944 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use